Allergen source materials: state-of-the-art

Area of Science:

• Pharmaceutical Manufacturing
• Public Health
• Pharmacovigilance

Background:

• Quality risk management is increasingly vital in public health, pharmacovigilance, and pharmaceutical manufacturing.
• Regulatory bodies are emphasizing risk assessment for issues like transmissible spongiform encephalopathies (TSE) agents and allergen product safety.

Purpose of the Study:

• To highlight the positive outcomes of validation and risk management activities.
• To demonstrate the application of quality risk management in complex pharmaceutical manufacturing environments.
• To showcase the utility of tools like Failure Mode and Effects Analysis (FMEA) in process evaluation.

Main Methods:

• Cross-functional team participation from quality, regulatory, legal, engineering, production, R&D, and sales/marketing.
• Application of quality risk management principles to allergen source material process validation.
• Utilizing Failure Mode and Effects Analysis (FMEA) for evaluating changes and feedback.

Main Results:

• Successful implementation of risk management strategies in complex manufacturing settings with numerous products.
• Effective evaluation of manufacturing procedure changes, regulatory actions, and customer feedback using FMEA.
• Demonstrated ability to manage risks associated with TSE agents and allergen extracts.

Conclusions:

• Validation and risk management activities yield significant positive outcomes, including reduced product failures.
• Proactive identification and prediction of potential product failures are improved.
• Increased confidence in overall product quality and safety is achieved through robust quality assurance programs.